In this era of targeted therapies, it is more critical than ever to begin with an accurate diagnosis. However, many diagnostics currently in use are inadequate¹. Until now, there has been an unmet need for accurate and time-efficient testing to determine primary origin.

miRview® mets is the first microRNA-based molecular diagnostic test designed for cancer of unknown primary (CUP). It offers:

• Accuracy
• Efficiency
• Validity
• Simple interpretation
• Quantitative analysis
• Objective results
• Cutting-edge molecular biology

1. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100(9):1776-1785.